Keep pumping the fear harding, I need more shares at these levels, I really need to retire in two years.
Btx owns 700 patents but as investors are now finding out the majority of those are useless embryonic patents.
MENLO PARK, Calif., June 1, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML). AST-VAC1 is the Company's autologous (using cells sourced from the patient) telomerase-based dendritic cell cancer vaccine. AML is the most common form of acute leukemia in adults with 12,000 new cases diagnosed annually, and remains an unmet clinical need, especially in patients over the age of 60 who face poor outcomes and have limited therapies available to them. The long-term follow-up showed that more than 50% of patients who received AST-VAC1 had prolonged relapse-free survival, even patients with high-risk AML including those over 60 years old and patients in second remission.
'Smoke & mirrors' are words used in order to create doubt so day traders can buy back in.
Biotime has over 600 key stem cell patents and seven subsidiaries so it's actually a very safe stock to buy and sell. Just be careful not to have all shares sold as we are approaching major upcoming milestones.
PanC-DX cancer diagnostic products on the way as well as GE/BTX drud testing stem cell kits.
Billion dollar pipeline about to flood market.
OncoCytes PanC-DX products take blood and urine samples, are quick, easy and cheap. Huge profit margins to be had. I for one will load up on the OncoCyte IPO!
Weil Cornell or Mt Sini?
You can't patent genes but you can the method for finding them. BTX will rock the cancer establishment.
Take for example the Asthma Health app, a joint effort of Mount Sinai Icahn School of Medicine and LifeMap Solutions, a subsidiary of BioTime, Inc. Eric Schadt, a professor of genomics at the Icahn School who spearheaded the collaboration, told Digital Trends that by using the app, “over 3,500 people consented and enrolled in our research study in less than 72 hours! It would have taken us years to get 3,500 people enrolled the traditional way.”
Why Was It So Successful?
The new platform allows someone to partake in a clinical study from the comfort of his or her own house, for free.
DigitalTrends explained how these apps, particularly Asthma Health, work.
“Developed within the framework of Apple's ResearchKit, Asthma Health aims to revolutionize the way clinical studies are done. The app has multiple uses. On one hand, it teaches patients to self-monitor and stick to their treatment plans. ‘A message will pop up and say, ‘you set up your reminder for 5pm–-did you use your inhaler?’ says Yu-Feng Yvonne Chan, director of personalized medicine and digital health at Icahn Institute at Mount Sinai. When users tap the screen to confirm they’re in compliance, they get a smiley face, which Chan says should ‘promote positive behavioral changes and adherence to treatment plans.’
"On the other hand, Asthma Health can track patients’ symptoms, flare-ups, and the triggers that cause them, sending all that info to a database so researchers can devise personalized treatments. In the future, if a patient has a flare-up on a particular date in a particular location, the software would analyze the GPS data, weather, air quality, and other factors to identify a probable cause. ‘We would note the triggers on this particular date—heat, humidity, or source of pollution,’ Chan says. ‘We would see patterns emerging and hopefully would provide patents with personalized feedback—such as ‘you are sensitive to this location, try to avoid it.’”